Trial Profile
A Cancer Research UK Phase I Trial of Anti-GD2 Chimeric Antigen Receptor (CAR) Transduced T-cells (1RG-CART) in Patients With Relapsed or Refractory Neuroblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2021
Price :
$35
*
At a glance
- Drugs AUTO 6 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Neuroblastoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 08 Feb 2021 Status changed from recruiting to completed.
- 30 Nov 2020 According to the Autolus media release, data from this study was published in Science Translational Medicine.
- 30 Nov 2020 Results published in the Autolus Media Release